Clinical Trials
-
News
What’s New In Clinical Trials For Thalassaemia/Sickle Cell Disease Drugs And Therapies?
Many pharmaceutical companies are making remarkable progress in their research into candidate treatments for these diseases and 2022 is expected to be yet another eventful year for haemoglobin disorders! Check…
Weiterlesen » -
News
Clinical Trials Update: The June 2021 Edition
TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
Weiterlesen » -
News
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
Weiterlesen » -
News
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Weiterlesen » -
News
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Weiterlesen » -
News
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases of high…
Weiterlesen » -
Clinical News
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
Weiterlesen » -
News
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
Weiterlesen » -
News
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
Weiterlesen » -
News
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…
Weiterlesen »